Public record
Fasting insulin: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Population data
How fasting insulin is distributed in US adults
In the 2021 to 2023 US national health survey, the median fasting insulin was 9.0 uU/mL in men aged 20 to 39 and 8.9 uU/mL in women aged 20 to 39. Half of people in each group fall below the median; the row notes give the range covering the middle 90%.
| Measure | Value | Note |
|---|---|---|
| Men 20 to 39, median | 9.0 uU/mL | middle 90% of people: 2.8 to 32.7; 310 people tested |
| Men 40 to 59, median | 10.2 uU/mL | middle 90% of people: 3.3 to 38.9; 388 people tested |
| Men 60 and over, median | 10.2 uU/mL | middle 90% of people: 3.3 to 30.8; 674 people tested |
| Women 20 to 39, median | 8.9 uU/mL | middle 90% of people: 3.7 to 35.2; 439 people tested |
| Women 40 to 59, median | 9.2 uU/mL | middle 90% of people: 3.1 to 35.5; 503 people tested |
| Women 60 and over, median | 8.6 uU/mL | middle 90% of people: 3.3 to 26.5; 756 people tested |
How this was calculated
Computed survey-weighted 5th, 50th and 95th percentiles from the CDC public file by sex and age band, using the sample weight WTSAF2YR. Groups with fewer than 50 people are left out.
US adults aged 20 and over who gave a sample in NHANES 2021 to 2023, CDC variable LBXIN (Insulin (uU/mL))
These are population distributions, not clinical reference ranges or treatment targets. They include people with and without health conditions and people on medication. Laboratories differ in method and units.